Pramlintide: a human amylin analogue reduced postprandial plasma glucose, insulin, and C-peptide concentrations in patients with type 2 diabetes.

Thompson RG, Gottlieb A, Organ K, Koda J, Kisicki J, Kolterman OG

Diabetic medicine : a journal of the British Diabetic Association1 Jul 1997Cited by 50 (Europe PMC)

PMID9223392DOI10.1002/(sici)1096-9136(199707)14:7<547::aid-dia390>3.0.co;2-uPepBankPUB-09223392

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In insulin-treated type 2 diabetes, pramlintide reduced mean postprandial glucose versus placebo.
In plain wordsIn insulin-treated type 2 diabetes, pramlintide reduced glucose after the meal compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreasePostprandial glucose in insulin-treated patients
Study
n = 12
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · infusion · 5 hAs given in this study (human).
Source sentences
Summary
Pramlintide infusion in the insulin-treated patients resulted in statistically significant reductions in mean glucose, insulin, C-peptide, and lactate concentrations during the 4-h period after the Sustacal test meal.
1 context sentence(design, population, supporting numbers)
Summary · context
a single-blind, randomized, cross-over study was conducted in 24 patients; 12 treated with exogenous insulin and 12 managed with diet and/or oral hypoglycaemic agents.
Report a problemFND-0922339201
02HumanRandomized controlled trialEfficacy outcome
In insulin-treated type 2 diabetes, pramlintide reduced mean postprandial insulin versus placebo.
In plain wordsIn insulin-treated type 2 diabetes, pramlintide reduced insulin after the meal compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreasePostprandial insulin in insulin-treated patients
Study
n = 12
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · infusion · 5 hAs given in this study (human).
Source sentences
Summary
Pramlintide infusion in the insulin-treated patients resulted in statistically significant reductions in mean glucose, insulin, C-peptide, and lactate concentrations during the 4-h period after the Sustacal test meal.
1 context sentence(design, population, supporting numbers)
Summary · context
a single-blind, randomized, cross-over study was conducted in 24 patients; 12 treated with exogenous insulin and 12 managed with diet and/or oral hypoglycaemic agents.
Report a problemFND-0922339202
03HumanRandomized controlled trialEfficacy outcome
In insulin-treated type 2 diabetes, pramlintide reduced mean postprandial C-peptide versus placebo.
In plain wordsIn insulin-treated type 2 diabetes, pramlintide reduced C-peptide after the meal compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreasePostprandial C-peptide in insulin-treated patients
Study
n = 12
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · infusion · 5 hAs given in this study (human).
Source sentences
Summary
Pramlintide infusion in the insulin-treated patients resulted in statistically significant reductions in mean glucose, insulin, C-peptide, and lactate concentrations during the 4-h period after the Sustacal test meal.
1 context sentence(design, population, supporting numbers)
Summary · context
a single-blind, randomized, cross-over study was conducted in 24 patients; 12 treated with exogenous insulin and 12 managed with diet and/or oral hypoglycaemic agents.
Report a problemFND-0922339203
04HumanRandomized controlled trialEfficacy outcome
In insulin-treated type 2 diabetes, pramlintide reduced mean postprandial lactate versus placebo.
In plain wordsIn insulin-treated type 2 diabetes, pramlintide reduced lactate after the meal compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreasePostprandial lactate in insulin-treated patients
Study
n = 12
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · infusion · 5 hAs given in this study (human).
Source sentences
Summary
Pramlintide infusion in the insulin-treated patients resulted in statistically significant reductions in mean glucose, insulin, C-peptide, and lactate concentrations during the 4-h period after the Sustacal test meal.
1 context sentence(design, population, supporting numbers)
Summary · context
a single-blind, randomized, cross-over study was conducted in 24 patients; 12 treated with exogenous insulin and 12 managed with diet and/or oral hypoglycaemic agents.
Report a problemFND-0922339204
05HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes managed with diet or oral agents, pramlintide reduced mean postprandial insulin versus placebo.
In plain wordsIn type 2 diabetes managed with diet or oral drugs, pramlintide reduced insulin after the meal compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreasePostprandial insulin in diet or oral therapy patients
Study
n = 12
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · infusion · 5 hAs given in this study (human).
Source sentences
Summary
Pramlintide infusion also resulted in significant reductions of mean insulin, C-peptide, and lactate concentrations, but not glucose concentrations, in the patients treated with diet and/or oral hypoglycaemic agents.
1 context sentence(design, population, supporting numbers)
Summary · context
a single-blind, randomized, cross-over study was conducted in 24 patients; 12 treated with exogenous insulin and 12 managed with diet and/or oral hypoglycaemic agents.
Report a problemFND-0922339205
06HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes managed with diet or oral agents, pramlintide reduced mean postprandial C-peptide versus placebo.
In plain wordsIn type 2 diabetes managed with diet or oral drugs, pramlintide reduced C-peptide after the meal compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreasePostprandial C-peptide in diet or oral therapy patients
Study
n = 12
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · infusion · 5 hAs given in this study (human).
Source sentences
Summary
Pramlintide infusion also resulted in significant reductions of mean insulin, C-peptide, and lactate concentrations, but not glucose concentrations, in the patients treated with diet and/or oral hypoglycaemic agents.
1 context sentence(design, population, supporting numbers)
Summary · context
a single-blind, randomized, cross-over study was conducted in 24 patients; 12 treated with exogenous insulin and 12 managed with diet and/or oral hypoglycaemic agents.
Report a problemFND-0922339206
07HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes managed with diet or oral agents, pramlintide reduced mean postprandial lactate versus placebo.
In plain wordsIn type 2 diabetes managed with diet or oral drugs, pramlintide reduced lactate after the meal compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreasePostprandial lactate in diet or oral therapy patients
Study
n = 12
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · infusion · 5 hAs given in this study (human).
Source sentences
Summary
Pramlintide infusion also resulted in significant reductions of mean insulin, C-peptide, and lactate concentrations, but not glucose concentrations, in the patients treated with diet and/or oral hypoglycaemic agents.
1 context sentence(design, population, supporting numbers)
Summary · context
a single-blind, randomized, cross-over study was conducted in 24 patients; 12 treated with exogenous insulin and 12 managed with diet and/or oral hypoglycaemic agents.
Report a problemFND-0922339207
08HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes managed with diet or oral agents, pramlintide did not significantly reduce postprandial glucose versus placebo.
In plain wordsIn type 2 diabetes managed with diet or oral drugs, pramlintide did not significantly reduce glucose after the meal versus placebo.
Peptide
Pramlintide (Symlin)
Outcome
No significant changePostprandial glucose in diet or oral therapy patients
Study
n = 12
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · infusion · 5 hAs given in this study (human).
Source sentences
Summary
Pramlintide infusion also resulted in significant reductions of mean insulin, C-peptide, and lactate concentrations, but not glucose concentrations, in the patients treated with diet and/or oral hypoglycaemic agents.
1 context sentence(design, population, supporting numbers)
Summary · context
a single-blind, randomized, cross-over study was conducted in 24 patients; 12 treated with exogenous insulin and 12 managed with diet and/or oral hypoglycaemic agents.
Report a problemFND-0922339208

Studies that did not test the peptide alone1

In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Pramlintide (Symlin).

09HumanNot a test of Pramlintide (Symlin) aloneObservational studyMechanism
In type 2 diabetes managed with diet or oral agents, pramlintide-related postprandial glucose reductions correlated with glycated haemoglobin.
In plain wordsIn type 2 diabetes managed with diet or oral drugs, glucose reductions with pramlintide were linked to glycated haemoglobin levels.
Peptide
Pramlintide (Symlin)
Outcome
Direction not reportedGlucose response correlation with glycated haemoglobin
Study
n = 12
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Within this latter group, reduction in postprandial glucose concentrations in individual patients correlated with glycated haemoglobin values.
1 context sentence(design, population, supporting numbers)
Summary · context
a single-blind, randomized, cross-over study was conducted in 24 patients; 12 treated with exogenous insulin and 12 managed with diet and/or oral hypoglycaemic agents.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-0922339209

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.